Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs

被引:18
|
作者
DeAngelo, Jessica [1 ]
Jarrell, Daniel [1 ]
Cosgrove, Richard [1 ]
Camamo, James [1 ]
Edwards, Christopher [1 ]
Patanwala, Asad E. [2 ]
机构
[1] Banner Univ Med Ctr Tucson, Dept Pharm Serv, Tucson, AZ USA
[2] Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, Tucson, AZ USA
关键词
anticoagulants; warfarin; blood coagulation factors; hemorrhage; INTERNATIONAL NORMALIZED RATIO; CONSENSUS GUIDELINES; THROMBOSIS;
D O I
10.1097/MJT.0000000000000643
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin reversal is conflicting. It has been hypothesized that 3-PCC may be less effective than 4-PCC because of relatively lower factor VII content. Study Question: The primary objective of this study was to compare international normalized ratio (INR) reversal between 3-PCC and 4-factor PCC (4-PCC) in warfarin-treated patients. The secondary objectives include comparing blood product use, total reversal costs, and cost-effectiveness between the groups. Study Design: This was a retrospective cohort study conducted in 2 affiliated, academic institutions in the United States. Consecutive adult patients who received 3-PCC or 4-PCC for warfarin reversal were included. Measures and Outcomes: The primary outcome was adequate INR reversal defined as a final INR <= 1.5. Secondary outcomes were the utilization of plasma, red blood cells and platelets, reversal costs, and the cost-effectiveness ratio. Results: There were 89 patients who were included in the overall cohort (3-PCC = 57, 4-PCC = 32). Adequate INR reversal occurred less commonly with 3-PCC (45.6%) compared with 4-PCC (87.5%) (P < 0.001). There was no significant difference in the proportion of patients who received plasma (32% vs. 28%, P = 0.813), red blood cells (37% vs. 47%, P = 0.377), or platelets (16% vs. 28%, P = 0.180) between the 3-PCC and 4-PCC groups, respectively. The median reversal cost of 3-PCC ($3663) was lower than 4-PCC ($5105) (P = 0.001). The cost-effective ratio favored 4-PCC ($5105/87.5% = $5834) compared with 3-PCC ($3663/45.6% = $8033). Conclusions: Four-PCC was more effective than 3-PCC with regard to INR reversal in patients taking warfarin, but blood product use was similar. Although 4-PCC is associated with increased reversal costs, it may be cost-effective in terms of INR reversal.
引用
收藏
页码:E326 / E332
页数:7
相关论文
共 50 条
  • [41] EVALUATION OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE DOSING FOR FACTOR XA INHIBITOR REVERSAL
    Craven, Cody
    Sbertoli, Robert
    Ramiro, Joanna
    Emery, Darrick
    Braun, James
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 436 - 436
  • [42] Anticoagulation Strategies in the Perioperative Period for Lung Transplant: 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal
    Barac, Y. D.
    Klapper, J.
    Poisson, J.
    Zaffiri, L.
    Pollack, A.
    Seay, T.
    Jawitz, O.
    Haney, J.
    Daneshmand, M.
    Welsby, I.
    Hartwig, M. G.
    Bottiger, B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S419 - S419
  • [43] Low-Dose 3-Factor Prothrombin Complex Concentrate for Warfarin Reversal Prior to Heart Transplant
    Kantorovich, Alexander
    Fink, Jodie M.
    Militello, Michael A.
    Wanek, Matthew R.
    Smedira, Nicholas G.
    Soltesz, Edward G.
    Moazami, Nader
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (08) : 876 - 882
  • [44] USE OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE IN CARDIOTHORACIC SURGERY
    Lee, Sue
    de Leon, Noelle
    Thompson, Ashley
    Baumgartner, Christine
    Fang, Margaret
    Prasad, Priya
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 608 - 608
  • [45] Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
    Maguire, Michelle
    Fuh, Lanting
    Goldstein, Joshua N.
    Marshall, Ariela L.
    Levine, Michael
    Howell, Melissa L.
    Parry, Blair A.
    Rosovsky, Rachel
    Hayes, Bryan D.
    WESTERN JOURNAL OF EMERGENCY MEDICINE, 2019, 20 (04) : 619 - 625
  • [46] Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage
    Abdalla A. Ammar
    Mahmoud A. Ammar
    Kent A. Owusu
    Stacy C. Brown
    Firas Kaddouh
    Aladine A. Elsamadicy
    Julián N. Acosta
    Guido J. Falcone
    Neurocritical Care, 2021, 35 : 255 - 261
  • [47] Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage
    Ammar, Abdalla A.
    Ammar, Mahmoud A.
    Owusu, Kent A.
    Brown, Stacy C.
    Kaddouh, Firas
    Elsamadicy, Aladine A.
    Acosta, Julian N.
    Falcone, Guido J.
    NEUROCRITICAL CARE, 2021, 35 (01) : 255 - 261
  • [48] Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate
    Sara Kjerengtroen
    Stephanie Chauv
    Abby W. Hickman
    Dave S. Collingridge
    Gabriel V. Fontaine
    Journal of Thrombosis and Thrombolysis, 2022, 54 : 268 - 275
  • [49] Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate
    Adams, Christopher B.
    Vollman, Kristan E.
    Leventhal, Evan L.
    Acquisto, Nicole M.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (06): : 1182.e1 - 1182.e2
  • [50] Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate
    Kjerengtroen, Sara
    Chauv, Stephanie
    Hickman, Abby W.
    Collingridge, Dave S.
    Fontaine, Gabriel, V
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 54 (02) : 268 - 275